A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]

Volume: 89, Issue: 9, Pages: S226 - S227
Published: May 1, 2021
Abstract
ZYN002 is a pharmaceutically manufactured transdermal cannabidiol gel. CONNECT-FX was a randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of ZYN002 in patients 3 to 17 years with full FMR1 gene...
Paper Details
Title
A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]
Published Date
May 1, 2021
Volume
89
Issue
9
Pages
S226 - S227
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.